Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Sells $20,835.00 in Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Floyd F. Petersen sold 500 shares of the business’s stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $41.67, for a total value of $20,835.00. Following the sale, the director now owns 78,833 shares of the company’s stock, valued at approximately $3,284,971.11. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Amphastar Pharmaceuticals Trading Down 0.5 %

Shares of AMPH stock opened at $42.46 on Friday. The stock has a market cap of $2.04 billion, a P/E ratio of 16.46, a price-to-earnings-growth ratio of 1.02 and a beta of 0.85. Amphastar Pharmaceuticals, Inc. has a 1 year low of $35.93 and a 1 year high of $67.66. The company has a current ratio of 2.17, a quick ratio of 1.70 and a debt-to-equity ratio of 0.92. The stock has a 50 day simple moving average of $43.48 and a 200 day simple moving average of $50.75.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its earnings results on Wednesday, February 28th. The company reported $0.81 earnings per share for the quarter, missing analysts’ consensus estimates of $0.84 by ($0.03). The company had revenue of $178.11 million for the quarter, compared to the consensus estimate of $174.90 million. Amphastar Pharmaceuticals had a net margin of 21.34% and a return on equity of 26.95%. On average, research analysts predict that Amphastar Pharmaceuticals, Inc. will post 3.41 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Amphastar Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the company. Shaker Investments LLC OH increased its holdings in Amphastar Pharmaceuticals by 136.0% in the 4th quarter. Shaker Investments LLC OH now owns 49,078 shares of the company’s stock valued at $3,035,000 after buying an additional 28,283 shares during the period. Jacobs Levy Equity Management Inc. raised its position in Amphastar Pharmaceuticals by 44.8% during the third quarter. Jacobs Levy Equity Management Inc. now owns 554,850 shares of the company’s stock valued at $25,518,000 after purchasing an additional 171,642 shares in the last quarter. Walleye Capital LLC bought a new stake in Amphastar Pharmaceuticals during the third quarter worth $1,833,000. Charles Schwab Investment Management Inc. lifted its stake in Amphastar Pharmaceuticals by 7.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 352,378 shares of the company’s stock worth $16,206,000 after purchasing an additional 24,116 shares during the last quarter. Finally, Rafferty Asset Management LLC acquired a new stake in shares of Amphastar Pharmaceuticals in the 3rd quarter valued at $205,000. Institutional investors own 65.09% of the company’s stock.

Analysts Set New Price Targets

AMPH has been the subject of several recent research reports. JPMorgan Chase & Co. assumed coverage on Amphastar Pharmaceuticals in a research note on Tuesday, March 5th. They issued an “overweight” rating and a $60.00 price target for the company. Needham & Company LLC reissued a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Wednesday, April 10th. Finally, StockNews.com downgraded shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, February 29th. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $66.00.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.